CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 11,464	$ 9,123
Marketable debt securities	816	130
Receivables	10,921	9,886
Inventories	2,662	2,339
Other current assets	5,907	5,795
Total Current assets	31,770	27,273
Property, plant and equipment	6,646	6,255
Goodwill	21,169	21,149
Other intangible assets	27,072	35,859
Deferred income taxes	2,768	1,344
Marketable debt securities	364	0
Other non-current assets	5,370	4,940
Total Assets	95,159	96,820
Current Liabilities:
Short-term debt obligations	3,119	4,264
Accounts payable	3,259	3,040
Other current liabilities	15,884	14,586
Total Current liabilities	22,262	21,890
Deferred income taxes	338	2,166
Long-term debt	36,653	35,056
Other non-current liabilities	6,421	6,590
Total Liabilities	65,674	65,702
Commitments and contingencies
Bristol-Myers Squibb Company Shareholders’ Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 2,953 in 2023 and 2,991 in 2022, liquidation value of $50 per share	0	0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2023 and 2022	292	292
Capital in excess of par value of stock	45,684	45,165
Accumulated other comprehensive loss	(1,546)	(1,281)
Retained earnings	28,766	25,503
Less cost of treasury stock — 902 million common shares in 2023 and 825 million common shares in 2022	(43,766)	(38,618)
Total BMS Shareholders’ Equity	29,430	31,061
Noncontrolling interest	55	57
Total Equity	29,485	31,118
Total Liabilities and Equity	$ 95,159	$ 96,820